Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial
about
Novel agents for advanced pancreatic cancerEvidence for the importance of personalized molecular profiling in pancreatic cancer.Association between PSCA mRNA expression levels and rs2294008 polymorphism in transitional cell cancer of the bladder.Common genetic variants in the PSCA gene influence gene expression and bladder cancer riskProstate stem cell antigen variation rs2294008 associated with the risk of bladder cancer.Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancerGlobal, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.Astellas' drug discovery strategy: focus on oncology.Prostate cancer vaccines in clinical trials.Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs.Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.Expression of prostate stem cell antigen is downregulated during flavonoid-induced cytotoxicity in prostate cancer cells.Association of PSCA rs2294008 gene variants with poor prognosis and increased susceptibility to gastric cancer and decreased risk of duodenal ulcer disease.
P2860
Q26787087-422E5D77-E60E-4F58-A22A-65EB9021F29DQ34387784-794D9C94-6072-479F-BF35-44639FCA062AQ34993937-2E0571F5-BCAA-4F46-A9C9-E49E8D2DEF9AQ35882541-74604418-3E47-4A90-976E-7CCF44C5E271Q36182999-CEF5C814-A52B-4FB1-AF74-BA6438C364E7Q36507544-B5596D8D-6F40-4E66-9630-7B40D9A03DC3Q37026797-A1DAD3A4-D2F6-45E6-BB71-5CB26B604ABDQ37506182-145F501B-B3CE-4D81-97ED-B380BC434A8CQ37998009-C3DA90C4-F8BB-4308-ACA6-7AF92D717246Q38036690-14AF72C5-A672-459B-A702-786C18F3A680Q38166831-680C5129-1CEB-4B5C-BBC9-792695861F0FQ38719148-E0294DBA-7666-431D-AB75-E77404131449Q38903708-2E893FD8-B322-487D-8D1B-250924FA50C9Q41116482-0E5ADBD4-5745-423C-B48F-5C1146C948DCQ41461702-F9941C8D-0E33-4786-BB1F-5821949BFB63
P2860
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Phase I rapid dose-escalation ...... prostate cancer: a PCCTC trial
@ast
Phase I rapid dose-escalation ...... prostate cancer: a PCCTC trial
@en
type
label
Phase I rapid dose-escalation ...... prostate cancer: a PCCTC trial
@ast
Phase I rapid dose-escalation ...... prostate cancer: a PCCTC trial
@en
prefLabel
Phase I rapid dose-escalation ...... prostate cancer: a PCCTC trial
@ast
Phase I rapid dose-escalation ...... prostate cancer: a PCCTC trial
@en
P2093
P2860
P1476
Phase I rapid dose-escalation ...... prostate cancer: a PCCTC trial
@en
P2093
Emmanuel S Antonarakis
Howard I Scher
Kathy Jelaca-Maxwell
Mario A Eisenberger
Martha E Vincent
Michael A Carducci
Michael J Morris
Samuel R Denmeade
Susan F Slovin
P2860
P2888
P304
P356
10.1007/S00280-011-1759-9
P577
2011-10-22T00:00:00Z